Clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory testing and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PF-ILD accompanies the development of individualized treatment plans, which typically include drug therapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored throughout the treatment process, and timely adjusted according to changing conditions. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD-associated macrophages. The platform serves the China International Medical Service System, which combines domestic and foreign authoritative teams of experts in the field of infectious respiratory digestive and endocrine secretion to provide the following services to patients: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangements with authoritative experts for face-to-face diagnosis, development of personalized treatment programs; 3. Full-service: One-stop services: Medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of changes in disease and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.